Investment

#AI #Business #Investment

Sanofi signs $20m research agreement with Atomwise  

Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet platform for computational discovery and research of up to five drug targets.  The agreement will see Atomwise receive $20 million from Sanofi to identify, synthesise, and advance lead compounds for up to five targets,… Read More

#Business & Investment #News

#Biologics / Biotechnology #Business #Clinical trials #Investment

Ryvu Therapeutics receives €22m to advance cancer portfolio  

Clinical-stage drug discovery company Ryvu Therapeutics has received €22 million from the European Investment Bank (EIB) to help it advance its portfolio of cancer treatments.   The funding, which is being provided under the EIB’s venture debt instrument, will help Ryvu finance its development pipeline of new cancer treatments from discovery… Read More

#Business & Investment #News

#Alderley Park #Business #Investment #Lab space

£20m lab redevelopment coming to UK 

Life sciences property provider Bruntwood SciTech has invested £20 million into redeveloped laboratories at the UK’s North West research campus, Alderley Park.   The £20 million investment has gone towards the redevelopment of existing lab spaces to create high-specification biology and chemistry containment level two (CL2) laboratory suites. The labs have… Read More

#Business & Investment #News

#Covid-19 #Investment #Latin America and the Caribbean (LAC)

IFC invests $30 million to improve healthcare in Latin America   

The International Finance Corporation (IFC) is investing $30 million in the pharmaceutical company Laboratorios Siegfried to help provide lower-income populations across the Latin America and the Caribbean (LAC) regions with better access to high-quality and affordable healthcare products.  The investment falls under IFC’s Global Health Platform (GHP) and will support… Read More

#Business & Investment #Covid-19 #News

#Business #Investment #Synthetic biology

Synthetic biology in UK gets £5.5m boost  

A UK centre for synthetic biology has received £5.5 million in funding so it can support start-ups and SMEs in the sector.  The UK’s National Centre for the Industrial Translation of Synthetic Biology, SynbiCITE, will use the funding to support businesses within the sector and to help… Read More

#News

#Business #Investment #Psychedelics

Origin Therapeutics adds Canadian psychedelics company to portfolio  

Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio.  Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with a Phase II… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Investment #Oncology

Spirea raises £2.4m to develop ADC cancer therapies  

A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.  Spirea is developing ACD therapeutics for solids tumours with a high unmet need. The company has developed technology that enables more cytotoxic drug to… Read More

#Business & Investment #News

#Clinical trial #Investment

uMotif raises $25.5m to expand clinical trial software  

uMotif today announced a new investment of $25.5 million from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif’s unique patient-first software platform for clinical research.  The company’s software is designed to provide… Read More

#News

#AI #Digital therapeutics #Immunotherapy #Investment

This week in drug discovery (23-27 May) 

News round-up by DDW’s Reece Armstrong for 23-27 May   UK investment plans, company appointments to drive strategy, and digital health platforms are some of the themes of this week’s news round-up.    New £20m fund launches to support North West life sciences  A new £20… Read More

#News

#Investment #Life sciences

New £20m fund launches to support North West life sciences

A new £20 million fund has been launched in the Northwest of England to help support the region’s life sciences sector. The ‘GMC Life Sciences Fund By Praetura’ is a partnership between Greater Manchester Combined Authority (GMCA), Cheshire and Warrington Local Enterprise Partnership (LEP), Bruntwood SciTech and Praetura Ventures. It… Read More

#Business & Investment #News

#Biologics / Biotechnology #Investment

Redx raises £34m after placement of shares  

Clinical-stage biotech Redx has raised £34 million in funding to help it progress its pipeline of therapeutics targeting cancer and fibrotic disease.   Redx raised the funding through a Bookbuild process in which a company generates investor demand when raising capital in an attempt to achieve the best… Read More

#News

#Biologics / Biotechnology #Biopharma #Investment #LSX World Congress #Supply chain

Comment – pharma trends at LSX World Congress  

The LSX World Congress returned for an in-person event in May, bringing together executives from the biotech, medtech and healthtech sectors, across two days to examine the latest trends across life sciences.  DDW’s Reece Armstrong attended the event – here are the key takeaways from the show.  One of the… Read More

#Exclusive Content #Opinion

#Biologics / Biotechnology #Investment #Swiss Biotech Report

Swiss biotech sector sees strong performance in 2021, report says   

Switzerland’s life sciences sector saw a strong year in 2021 with companies contributing to the Covid-19 pandemic and high levels of capital investments being key indicators of the sector’s strength.   This is according to the latest edition of the Swiss Biotech Report1 which was launched by the Swiss Biotech Association.  … Read More

#Business & Investment #News

#Business #Finance #Investment

BioXcel Therapeutics raises $260m to support commercial activities

BioXcel Therapeutics has raised $260 million in funding to support the commercial activities of its proprietary, orally dissolving film formulation IGALMI. Previously known as BXCL501, IGALMI is an orally dissolving film formulation of dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder… Read More

#News

#Acquisition #Investment #Supply chain

Ilya Pharma acquires Nordic Bioanalysis to bolster supply chain 

Immunotherapy company Ilya Pharma has acquired Nordic Bioanalysis in a move to strengthen its supply chain and help develop its pipeline of skin and mucosal immunotherapy drug candidates.  Nordic Bioanalysis was founded in 2019 and serves as an international expert in bioanalytical development and validation for pharmaceuticals,… Read More

#News

#Evotec #Finance #Innovation #Investment #Pharma

Is Toulouse France’s hidden hub of life sciences innovation? 

DDW Deputy Editor Reece Armstrong recently attended the Invest in Toulouse Virtual Round Table to find out how the city is establishing itself as a place of exciting research in the healthcare sectors.   Hosted by Jean-Claude Dardelet, the city’s Deputy Mayor, the roundtable examined how Toulouse is becoming an international… Read More

#Market Reports #News